한글목차

두경부암 치료제 시장은 2025년에는 22억 8,660만 달러로 추정되며, 2032년에는 37억 4,450만 달러에 달할 것으로 예측되며, 2025-2032년의 연평균 성장률(CAGR)은 7.3%로 성장할 것으로 예측됩니다.

두경부암은 코, 인두, 부비동, 후두, 입 주변에 발생하는 다양한 악성 종양을 일컫는 의학 용어입니다. 두경부암의 대부분은 편평상피암입니다. 두경부암은 조기에 발견하면 완치 가능성이 높지만, 치료는 여러 가지 요인에 따라 달라집니다.

시장 역학

두경부암 부담 증가, 질병 진단에 대한 관심 증가, 담배 흡연, 음주, 다량 사용 증가, 안전하고 효과적인 약물 및 치료에 대한 높은 수요, 연구개발 증가는 세계 두경부암 치료제 시장의 성장을 증가시킬 것으로 예상되는 주요 요인입니다.

예를 들어 2022년 2월, 신시내티 대학 연구진은 국소 방사선 치료와 면역 요법의 조합이 재발성 경부암 환자에게 더 나은 치료법이 될 수 있는지 여부를 검토하는 새로운 임상시험을 시작했습니다.

또한 2021년 2월 미국 FDA는 Kura Oncology, Inc.가 개발한 Tipifarnib을 두경부 편평상피암(HNSCC) 환자 치료제로 획기적 치료제로 지정했습니다. 이 약은 강력하고 선택적인 경구용 약물입니다.

본 조사의 주요 특징

• 세계의 두경부암 치료제 시장을 상세하게 분석하여 2024년을 기준 연도, 2025-2032년의 예측 기간 시장 규모(USD Mn)와 연평균 성장률(CAGR)을 조사하여 정리한 보고서입니다.
• 또한 다양한 부문에 걸친 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 인사이트을 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 두경부암 치료제 시장의 주요 기업 개요을 제공합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계의 두경부암 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 두경부암 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 리포트 설명
  • 시장의 정의와 범위
• 개요
• Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 두경부암의 이환율 증가
  • 두경부암 치료제의 부작용
  • 안전하고 효과적인 의약품의 수요 증가
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 발매/승인
• PEST 분석
• PORTER의 산업 분석
• 합병과 인수 시나리오

제4장 세계의 두경부암 치료제 시장, 약제 클래스별, 2020-2032년

• 화학요법
• 면역치료
• 표적치료

제5장 세계의 두경부암 치료제 시장, 판매 채널별, 2020-2032년

• 병원 약국
• 드러그스토어와 약국
• 온라인 스토어

제6장 세계의 두경부암 치료제 시장, 지역별, 2020-2032년

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• Merck & Co., Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Astrazeneca Plc.
• Fresenius Medical Care AG & CO. KGAA
• F. Hoffmann-la Roche Ltd.(Genentech, Inc.)

제8장 섹션

• 조사 방법
• 출판사 소개

영문목차

Head and Neck Cancer Drugs Market is estimated to be valued at USD 2,286.6 Mn in 2025 and is expected to reach USD 3,744.5 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032.

Head and neck cancer is a medical term used to describe different malignant tumors that develop in or around the nose, throat, sinuses, larynx, and mouth. Most head and neck cancers are squamous cell carcinomas. Head and neck cancer is highly curable if detected early, however, the treatment depends on a number of factors.

Market Dynamics

Growing burden of head and neck cancer, rise in focus on disease diagnosis, increase in cigarette smoking, alcohol consumption, and high use of tobacco, high demand for safe and effective drugs or treatment, and increasing research and development are major factors expected to augment the growth of the global head and neck cancer drugs market.

For instance, in February 2022, University of Cincinnati researchers launched a new clinical trial to examine if the combination of a localized radiation treatment and immunotherapy can be a better treatment for patients with recurrent head and neck cancer.

Moreover, in February 2021, the U.S. FDA granted breakthrough therapy designation to Tipifarnib developed by Kura Oncology, Inc., for the treatment of patients with head and neck squamous cell carcinoma (HNSCC). This is a potent, selective, and orally administered drug.

Key features of the study

• This report provides in-depth analysis of the global head and neck cancer drugs market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global head and neck cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Astrazeneca Plc., Fresenius Medical Care AG & CO. KGAA, and F. Hoffmann-la Roche Ltd. (Genentech, Inc.,), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global head and neck cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global head and neck cancer drugs market.

Market Segmentation

• Global Head and Neck Cancer Drugs Market, By Drug Class
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
• Global Head and Neck Cancer Drugs Market, By Sales Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Stores
• Global Head and Neck Cancer Drugs Market, By Geography
  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Astrazeneca Plc.
  • Fresenius Medical Care AG & CO. KGAA
  • F.Hoffmann-la Roche Ltd. (Genentech, Inc.)

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Sales Channel
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of head and neck cancer
  • Adverse effects of head and neck cancer drugs
  • Increasing demand for safe and effective drugs
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Head and Neck Cancer Drugs Market, By Drug Class, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Immunotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Targeted Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)

5. Global Head and Neck Cancer Drugs Market, By Sales Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Drug Stores & Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Online Stores
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)

6. Global Head and Neck Cancer Drugs Market, By Geography, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn) Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • South Africa
    • North Africa
    • Central Africa

7. Competitive Landscape

• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astrazeneca Plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fresenius Medical Care AG & CO. KGAA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F. Hoffmann-la Roche Ltd. (Genentech, Inc.)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us